Beatrice Raone

A double-blind, randomized, vehicle-controlled clinical study to evaluate the efficacy and safety of MAS063DP (ATOPICLAIR) in the management of atopic dermatitis in paediatric patients.

A multicenter, randomized, double‐blind, vehicle‐controlled clinical study was conducted to evaluate the efficacy and safety of MAS063DP in 60 paediatric patients affected by atopic dermatitis (AD), aged between 2 and 17 years. Using the Investigator’s Global Assessment (IGA) score for AD, patients with a score of 2 (mild) or 3 (moderate) were enrolled in the study. Patients were randomly selected to receive MAS063DP (20 patients), MAS060 (20 patients, a similar formulation with lower key ingredients’ concentration and no preservatives) or vehicle (20 patients).The study consisted in a treatment period of 43 days, with clinical evaluations at baseline (day 1), days 8, 15, 22, 29 and 43, at which time the treatment was stopped. MAS063DP showed nearly 80% improvement in IGA score at day 22, compared with 16.6% and 26.3% with the MAS060 and vehicle respectively. A statistically significant difference was found by comparing MAS063DP with MAS060 (p < 0.0001); a similar result was evidenced comparing MAS063DP and vehicle (p = 0.001). By contrast, no significant difference was found between MAS060 and vehicle. A statistically significant difference was sustained until the end of the study. MAS063DP may therefore be considered as one of the available regimens effective in the treatment of mild‐to‐moderate AD in children and adolescents.

Recurrent Toxin-Mediated Perineal Erythema: Eleven Pediatric Cases

BACKGROUND Recurrent toxin-mediated perineal erythema is a cutaneous disease mediated by superantigens made by staphylococci and streptococci, which, to our knowledge, has only been reported in young adults. We describe recurrent toxin-mediated perineal erythema in 11 children and outline the differences between recurrent toxin-mediated perineal erythema and Kawasaki disease in this age range. OBSERVATIONS Eleven children (7 male and 4 female) presented with the sudden appearance of asymptomatic erythema, which was salmonlike in color and rapidly desquamating, involving the perineum in 10 patients and extending to the perianal area in 1 patient. At the onset of the rash, all patients were in good health, although 9 had mild fever for 1 to 2 days before its appearance. Physical examination also revealed an erythema of the hands and feet in 4 patients and strawberry tongue in 7. Two patients had a facial impetigo, and another showed a perianal streptococcal dermatitis. A group A beta-hemolytic streptococcus was isolated from the throat in 10 cases and from a perianal culture in 1 case. In 8 cases, resolution was spontaneous, but all patients were treated with systemic antimicrobial therapy for 10 days. Three patients had a personal history of cutaneous rashes on the perineal area during the last years before consultation. Rash recurrence was observed in 3 of the 11 patients at the follow-up examination. Conclusion Recurrent toxin-mediated perineal erythema can be observed not only in young adults but also in childhood.

Infantile Perianal Protrusion: 13 New Cases

We report 13 girls, ages 4 months–5 years, affected by an infantile perianal protrusion located on the midline anterior to the anus in 8 patients and posteriorly in 3. A past personal history of constipation existed in six patients and anal fissures in three patients. In one of the five patients with recurrent anogenital erythema, a punch biopsy specimen revealed the histopathologic signs of lichen sclerosus et atrophicus (LS&A). In another two patients, infantile perianal protrusion was associated with clinical signs of genital LS&A. None of our patients had spontaneous reduction of infantile perianal protrusion during the follow‐up period.

Management of atopic dermatitis: safety and efficacy of phototherapy

Atopic dermatitis (AD) is a common chronic inflammatory skin disease that can affect all age groups. It is characterized by a relapsing course and a dramatic impact on quality of life for patients. Environmental interventions together with topical devices represent the mainstay of treatment for AD, in particular emollients, corticosteroids, and calcineurin inhibitors. Systemic treatments are reserved for severe cases. Phototherapy represents a valid second-line intervention in those cases where non-pharmacological and topical measures have failed. Different forms of light therapy are available, and have showed varying degrees of beneficial effect against AD: natural sunlight, narrowband (NB)-UVB, broadband (BB)-UVB, UVA, UVA1, cold-light UVA1, UVA and UVB (UVAB), full-spectrum light (including UVA, infrared and visible light), saltwater bath plus UVB (balneophototherapy), Goeckerman therapy (coal tar plus UVB radiation), psoralen plus UVA (PUVA), and other forms of phototherapy. In particular, UVA1 and NB-UVB have gained importance in recent years. This review illustrates the main trials comparing the efficacy and safety of the different forms of phototherapy. No sufficiently large randomized controlled studies have been performed as yet, and no light modality has been defined as superior to all. Parameters and dosing protocols may vary, although clinicians mainly refer to the indications included in the American Academy of Dermatology psoriasis guidelines devised by Menter et al in 2010. The efficacy of phototherapy (considering all forms) in AD has been established in adults and children, as well as for acute (UVA1) and chronic (NB-UVB) cases. Its use is suggested with strength of recommendation B and level of evidence II. Home phototherapy can also be performed; this technique is recommended with strength C and level of evidence III. Phototherapy is generally considered to be safe and well tolerated, with a low but established percentage of short-term and long-term adverse effects, with the most common being photodamage, xerosis, erythema, actinic keratosis, sunburn, and tenderness. A carcinogenic risk related to UV radiation has not been excluded. Phototherapy also has some limitations related to costs, availability, and patient compliance. In conclusion, phototherapy is an optimal second-line treatment for AD. It can be used as monotherapy or in combination with systemic drugs, in particular corticosteroids. It must be performed conscientiously, especially in children, and must take into account the patient’s features and overall condition.

Usefulness of dermatoscopy for the early diagnosis of sebaceous naevus and differentiation from aplasia cutis congenita

In early infancy, a congenital area of alopecia of the scalp may be the clinical presentation of various diseases, with the two most common being sebaceous naevus and aplasia cutis congenita. Typical lesions are easily diagnosed, but soon after birth, the differential diagnosis may be difficult if the clinical features of the lesion are not distinctive. In this paper, we report the usefulness of dermatoscopy in such cases.

Circulating Autoantibodies and Autoimmune Comorbidities in Vitiligo Patients: A Multicenter Italian Study

Background: Autoimmune comorbidities and circulating autoantibodies have been observed in vitiligo patients, but differences in rate are present according to countries in which the studies were performed, perhaps owing to ethnic diversities or different trigger factors. Objective: To estimate the prevalence of circulating autoantibodies and overt autoimmune diseases in a fairly large sample of Italian vitiligo patients. Methods: 175 outpatients affected by vitiligo and referred to nine dermatological centers were included in the study. Patients were offered routine blood test, serological testing for thyroid function and search for autoantibodies. Results: At least one circulating autoantibody was detected in 61 (41.8%) of 146 subjects who underwent laboratory tests. Anti-thyroperoxidase (25.6%), anti-thyroglobulin (23.4%), antinuclear antibodies (16.8%) and anti-gastric parietal cell antibodies (7.8%) were the most noticed autoantibodies. 74 (41.5%) autoimmune comorbidities, mainly autoimmune thyroiditis (37%), were reported. Conclusion: The prevalence of autoimmune comorbidities and circulating autoantibodies in this study was in agreement with other surveys conducted on Caucasian patients.

Overweight, diabetes and disease duration influence clinical severity in Hidradenitis Suppurativa ‐ Acne Inversa. Evidence from the national Italian Registry

DEAR EDITOR, Hidradenitis suppurativa–acne inversa (HS-AI) is a chronic inflammatory skin condition that involves the folliculopilosebaceous units. Histopathological studies have suggested that the occlusion of the follicular infundibulum and both innate and adaptive immunity play central roles. Limited data regarding the clinical aspects and prognosis of HS-AI are available. This paper presents data collected within the newly implemented Italian registry of patients with HS-AI. This was a cross-sectional study on baseline data of a cohort of consecutive patients with a new diagnosis of HS-AI, prospectively observed within a network of Italian dermatology departments. Presence and recurrence, for at least 6 months, of nodules, abscesses, draining sinuses and secondary retracting scars localized on the axillae, suband intermammary areas, inguinal folds, buttocks and perianal areas were considered as inclusion criteria. Written informed consent was obtained from the patients, or from their parents for subjects younger than 18 years, before inclusion in the registry. The study was approved by the ethics committee of the Sant’Anna Hospital in Ferrara. The information collected, using a standardized data collection form, included demographic data, anthropometric measures, selected personal habits, clinical history of the disease, clinical features at entry and follow-up, presence of comorbidities, and therapies prescribed for at least 1 month. The severity of HS-AI was assessed by a physician using the Sartorius score. A short course was run among participants to harmonize Sartorius score calculation, and the inter-rater agreement of independent measures obtained by participants on a small series of patients was judged satisfactory (data not shown). Age-standardized prevalence rates were computed using the 2011 Italian population as a reference. The frequency distribution of selected variables within the HS-AI sample was compared with the distribution in the general population using standardized prevalence ratios along with their 95% confidence intervals (CIs). The Mann–Whitney U-test and Kruskal–Wallis test were used to assess differences across different levels of selected variables for HS severity. To assess which factors were independently associated with HS severity, baseline variables with a P-value < 0 10 in the univariate analysis were evaluated in multivariate linear regression models with forward stepwise selection algorithms. The effects of selected factors were expressed in terms of standardized (Pearson) correlation coefficients (q) along with their 95% CIs and P-values. All tests were considered significant at P < 0 05. From January 2009 to June 2013, 245 patients in seven Italian referral centres for HS-AI were included in the registry; 59 6% of patients were female, and the age at entry was between 6 and 85 years (mean 33 4 13 0), with a mean age at first diagnosis by a physician of 28 2 11 8 years, and a mean Sartorius score of 78 4 66 1 (Table 1). The mean age at onset of the disease was 21 3 10 2 years, and the main affected locations at baseline were the groin/genitals (44 1%), axillae (34 7%), buttocks (10 2%) and trunk (9 0%). The most frequently reported comorbidities were acne (5 7%), thyroid diseases (4 5%) and diabetes (4 1%). Compared with the general Italian population, adult patients (aged ≥ 18 years) with HS-AI were more frequently overweight or obese (age-standardized prevalence ratio 1 4, 95% CI 1 1–1 9), and the prevalence of current smokers was substantially higher (age-standardized prevalence ratio 2 5, 95% CI 1 9–3 4). There were some significant variations between sexes. Age at onset was higher in male patients (24 2 12 7 vs. 19 4 7 6, P = 0 003), while groin/genital involvement was more frequent in female patients (50 7% vs. 34 3%, P = 0 01). In the univariate analysis, age, duration of disease, diagnostic delay, body mass index (BMI), smoking habits and presence of diabetes were all associated with an increased severity of the disease at baseline (Table 2). In the multivariate analysis, duration of disease ≥ 5 years, obesity (BMI ≥ 30 kg m ) and the presence of diabetes were maintained as independent factors directly associated with HS-AI severity. Further analysis showed that smoking correlated with both duration of disease and BMI, with a significant linear trend across different levels of the variables (data not shown). Our data show that the implementation of a registry for HS-AI is feasible and could provide useful data to direct disease management. Smoking and obesity have been proposed as risk factors either to trigger or to exacerbate HS-AI. In our cohort approximately 70% of the patients were current smokers (65 7%) or ex-smokers (8 6%), and the number of current smokers was higher than in the general Italian population. However, we lacked a control group of smokers matched for BMI. Smoking has been associated with increased severity of HS-AI in some studies but not others. In our study smoking

Tattoo-associated Pseudolymphomatous Reaction and its Successful Treatment with Hydroxychloroquine

Tattooing has become increasingly popular in today’s society, although it has been practiced for over 8000 years (1). Following this new fashion trend, physicians have documented an increasing number of tattoo-associated skin disorders.The most common dermatological tattoo compli-cations concern hypersensitivity reactions to tattoo pigments, for example, irritant and allergic contact dermatitis (2), development of lichenoid areas (1, 3–5), and granulomatous responses such as sarcoid granulo-mas or foreign body granulomas (1). Less frequently patients developing discoid lupus erythematosus have been reported (2).Pseudolymphoma confined to the tattoo area is an unusual tattoo reaction that, to the best of our knowledge, has been described in only seven cases in the literature (6–10). We report here a new case of pseudolymphoma developing in the green portion of a multicoloured tattoo, which was treated with a systemic anti-malarial drug.CASE REPORT

Atopic dermatitis and the atopic march: what is new?

Objective. In this paper the authors review the management of atopic dermatitis (AD) and the association between AD and allergic respiratory diseases. Data Sources. PubMed databases, researching articles in the last 15 years. Results. Studies about atopic march are cross-sectional population studies at different ages. They show that the most important predisposing factor for atopy is a decrease of the filaggrins expression. Conclusions. The most modern theories seem to show that the most important factor which starts the atopic march is represented by an impaired epidermal barrier. It causes an increase in skin permeability to allergens that could induce sensitization even in the airways. The major predisposing factor is a primary inherited epithelial barrier defect resulting from filaggrin gene mutation, but other factors may play a role in this complex mechanism. Further studies are needed to focus on AD treatment and preventive strategies.

Generalized Erythema Multiforme after Localized Allergic Dermatitis from Dark Henna Tattoo

Letters to the Editor are welcomed for publication (subject to editing). Letters must be signed by all authors, and must not exceed two pages of text including references. Letters should not duplicate material submitted or published in other journals. Prepublication proofs will not be provided.